Results 271 to 280 of about 481,368 (398)

Unique Findings of Sickle Cell Retinopathy in a Patient with Hemoglobin SE Disease. [PDF]

open access: yesJ Ophthalmic Vis Res
Lacher C   +5 more
europepmc   +1 more source

Harnessing the Immunomodulation of UV‐Exposed Keratinocyte Extracellular Vesicles for Inflammatory Disorder Treatment

open access: yesAdvanced Science, EarlyView.
Adopting a paradigm shift that transforms a known health hazard as a potential therapeutic asset, a novel therapeutic strategy is set out to investigate for inflammatory conditions by leveraging immunosuppressive properties of UV‐irradiated keratinocytes.
Lu Liu   +16 more
wiley   +1 more source

Subconjunctival dexamethasone implant (Ozurdex) for peripheral ulcerative keratitis. [PDF]

open access: yesAm J Ophthalmol Case Rep
Ghoraba HH   +6 more
europepmc   +1 more source

Tunneling Nanotube‐Mediated Transcellular Autophagy Alleviates Cadmium Induced Hepatocyte Injury

open access: yesAdvanced Science, EarlyView.
ROS accumulation is an important upstream signal for activating transcellular autophagy. Incomplete autophagy and TNT formation are necessary conditions for activating transcellular autophagy, and the disruption of the autophagic fusion mechanism is a trigger for activating transcellular autophagy.
Tao Wang   +13 more
wiley   +1 more source

Autologous Retinal Transplant in Refractory Macular Holes. [PDF]

open access: yesJ Vitreoretin Dis
Al-Assil T   +8 more
europepmc   +1 more source

A Nanomodulator Enhances Radiotherapy‐Induced In Situ Cancer Vaccine by Promoting Antigen‐Presenting of Tumor‐Associated Macrophage

open access: yesAdvanced Science, EarlyView.
A nanomodulator (Ft‐E64/Hf@Lipo) is developed, combining radiosensitizer hafnium (Hf) and the cysteine protease inhibitor E64, which cooperatively reinvigorated the antigen presentation of TAMs. Ft‐E64/Hf@Lipo sensitized‐RT generated abundant tumor neoantigens, and then E64/antigens, along with the apoptotic tumor cells, trafficked to TAMs via ...
Xiu Zhao   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy